LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease
LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a clinical trial evaluating their first-in-class allogenic regenerative cell therapy transplanted into patients’ lymph nodes…
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic cancer increased by 1% from the previous year to 12%. The increase has generated more optimism from the Pancreatic Cancer Action Network (PanCAN), whose President and CEO Julie…
India’s Fight for the Future: Tackling Sickle Cell Disease with Stem Cell Transplants
India is home to over 20 million individuals affected by Sickle Cell Disease (SCD), a genetic disorder causing abnormal, sickle-shaped red blood cells. The stakes are high, with a significant percentage of children not surviving past the age of five….
